The Food and Drug Administration Friday approved a new dosage option for buprenorphine and naloxone sublingual film, applied under the tongue as a maintenance treatment for opioid dependence. The medication-assisted treatment was approved through an abbreviated pathway under the Federal Food, Drug, and Cosmetic Act, which may rely on the FDA’s finding that a previously approved drug is safe and effective. “There’s an urgent need to ensure access to, and wider use and understanding of, medication-assisted treatment for opioid use disorder,” said FDA Commissioner Scott Gottlieb, M.D. “The introduction of new treatment options has the potential to broaden access for patients.”
 

Related News Articles

Perspective
The federal government has a history of reimbursing hospitals below of the cost of providing care to patients.For Medicare, which covers more than 60 million…
Headline
Hospitals and health systems are prioritizing preserving access to care for patients in rural America, including via access points like hospital outpatient…
Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Blog
September is National Suicide Prevention Month, with several days that emphasize the opportunity to elevate awareness about the important role everyone can…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Opinion / Editorial
This Op-Ed originally appeared in The Hill. Will the care be there? A confluence of unprecedented challenges over the last three years, including workforce…